BioSpace News Archive

IMBRUVICA® pooled clinical trial analyses presented at ASH demonstrate sustained efficacy and safety in patients with historically poor outcomes

Adoptive immunotherapy under investigation for children and adults with relapsed acute leukemia after allogeneic hematopoietic stem cell transplantation

Acquisition of Oncopia Therapeutics and research collaboration with lab of Dr. Shaomeng Wang at the University of Michigan to add diverse pipeline of current and future compounds

Zanubrutinib was shown to be highly active in patients with relapsed/refractory marginal zone lymphoma in initial results from the Phase 2 MAGNOLIA trial

Clinical benefit rate of 73% reported in second line relapsed AML patients. Overall Response OOR 45%, CR/CRi rate of 36%

Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, announced that Sinovac Life Sciences Co., Ltd., a subsidiary of Sinovac, has secured approximately US$500 million in funding for further development, capacity expansion and manufacturing of the CoronaVac, its COVID-19 vaccine candidate, as well as conduct other development and operational activities.

Oncopeptides AB, a pharmaceutical company focused on the development of targeted therapies for difficult-to-treat hematological diseases announces updated efficacy and safety data from the ongoing phase 2 ANCHOR combination study, following an oral presentation at the 62nd American Society of Hematology virtual annual meeting.